Overview: Dengue NS1 Antigen Rapid TestIntroduction: The Dengue NS1 Antigen Rapid Test is a diagnostic tool designed to detect Dengue NS1 antigen in whole blood, serum, plasma, or saliva samples, facilitating the screening of dengue fever. Caused by the Dengue virus transmitted by Aedes mosquitoes, this viral infection presents with high fever, joint pain, and severe complications like dengue hemorrhagic fever or shock syndrome if untreated, particularly in tropical and subtropical regions. Per the 2023 World Health Organization guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis during outbreaks. This rapid diagnostic falls under virology and targets individuals with recent fever or travel history, addressing the challenge of early detection to guide supportive care and prevent severe outcomes. With morbidity rates elevated due to epidemic potential, the test supports public health efforts by enabling early case identification, facilitating vector control, and reducing transmission. Its multi-sample capability enhances its utility in diverse clinical settings.Other Names: Dengue NS1 Rapid Test.FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by SD Bioline, this test advanced dengue detection, providing a rapid alternative to serology.Purpose: The test screens for Dengue NS1 antigen to guide fever diagnosis, assess disease stage, and inform treatment and prevention strategies.Test Parameters: Presence of Dengue NS1 Antigen, detected with high specificity to indicate acute infection, typically detectable within 1-7 days of symptom onset.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, joint pain, or recent travel to endemic areas.Specimen: Whole Blood 2-5 mL, Serum 2-5 mL, Plasma 2-4 mL, Saliva 1-2 mL, collected using sterile EDTA or SST tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fever, joint pain, rash, or recent mosquito exposure, as well as any prior dengue infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including shock, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or late infection after antigen clearance can affect results. Correlation with PCR or serology is recommended to confirm findings.Clinical Significance: A positive result indicates dengue infection, necessitating supportive care and monitoring. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the antigen detection window.Specialist Consultation: Infectious disease specialists or tropical medicine experts should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: Dengue PCR, IgM/IgG serology, or platelet count for confirmation.Test Limitations: The test may produce false negatives in secondary infections or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes molecular methods.References: WHO Guidelines 2023, Journal of Virology 2024, Tropical Medicine and International Health 2025.